Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lerociclib in Participants With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant must be 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.~2. Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer.~3. Advanced (locoregionally recurrent not amenable to curative therapy, eg, surgery and/or radiotherapy, or metastatic) breast cancer~4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.~5. Adequate bone marrow and organ function~6. Female that is not pregnant and agrees to contraceptive use that is consistent with local regulations regarding the methods of contraception to be used during the study~7. Males agree to use a highly effective method of contraception and will refrain from donating sperm from the first dose of any study intervention~8. Participant is capable of giving signed informed consent~Exclusion Criteria:~1. Symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the Investigator's best judgment.~2. Peritoneal carcinomatosis.~3. Inflammatory breast cancer at screening.~4. Participant with central nervous system (CNS) involvement unless they are at least 4 weeks from prior therapy completion to starting the study treatment and have stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases.~5. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality~6. Has a history of prolonged QT syndrome or Torsades de Pointes~7. Has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy) or any CDK4/6 inhibitor.~8. Has received prior treatment with fulvestrant.~9. Use of systemic estrogens~10. Participant is currently receiving any of the following substances and cannot be discontinued 14 days prior to start the treatment:~    * Known strong or moderate CYP3A inducers or strong inhibition of CYP3A~   * Substances that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.~11. Echocardiogram done within the past 12 months with ejection fraction of ≤ 45% or documented history of congestive heart failure with reduced ejection fraction.~12. Evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or oral temperature \> 38°C at screening~13. Interstitial pneumonia or severe impairment of lung function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lerociclib + letrozole or fulvestrant (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).